Celladon (CLDN) began trading on the NASDAQ on 30 January 2014

Celladon Corp. (CLDN), a clinical-stage biotechnology company focused in the field of SERCA enzymes, announced Wednesday that it has priced its initial public offering of 5.5 million shares of its common stock at $8.00 per share.

Celladon has also granted the underwriters a 30-day option to purchase up to an additional 825,000 shares of common stock to cover overallotments, if any.

Celladon's common stock is scheduled to begin trading on the NASDAQ Global Market on January 30 under the symbol "CLDN". The company noted that the offering is scheduled to close on February 4, subject to customary closing conditions.

Barclays is acting as the sole book-running manager for the offering. Stifel and Wedbush PacGrow Life Sciences are acting as co-managers.

Address

Suite 240, 12760 High Bluff Drive
SAN DIEGO, CA 92130
United States 

Website 

http://www.celladon.net